Modified-release recombinant human TSH (MRrhTSH) augments the effect of (131)I therapy in benign multinodular goiter: results from a multicenter international, randomized, placebo-controlled study

H Graf, S Fast, F Pacini, A Pinchera, A Leung, M Vaisman, C Reiners, J L Wemeau, D Huysmans, Willie F. Harper, A Driedger, H Noemberg de Souza, M G Castagna, L Antonangeli, L Braverman, R Corbo, C Düren, E Proust-Lemoine, M A Edelbroek, C MarriottI Rachinsky, Peter Grupe, T Watt, J Magner, L Hegedus

    44 Citations (Scopus)

    Abstract

    Recombinant human TSH (rhTSH) can be used to enhance (131)I therapy for shrinkage of multinodular goiter (MG). OBJECTIVE, DESIGN, AND SETTING: The objective of the study was to compare the efficacy and safety of 0.01 and 0.03 mg modified-release (MR) rhTSH as an adjuvant to (131)I therapy, vs. (131)I alone, in a randomized, placebo-controlled, international, multicenter study.
    Original languageEnglish
    JournalJournal of Clinical Endocrinology and Metabolism
    Volume96
    Issue number5
    Pages (from-to)1368-76
    Number of pages9
    ISSN0021-972X
    DOIs
    Publication statusPublished - 2011

    Keywords

    • Adult
    • Aged
    • Aged, 80 and over
    • Anatomy, Cross-Sectional
    • Combined Modality Therapy
    • Delayed-Action Preparations
    • Double-Blind Method
    • Female
    • Goiter, Nodular
    • Humans
    • Iodine Radioisotopes
    • Male
    • Middle Aged
    • Quality of Life
    • Recombinant Proteins
    • Thyroid Function Tests
    • Thyroid Hormones
    • Thyroidectomy
    • Thyrotropin
    • Trachea

    Fingerprint

    Dive into the research topics of 'Modified-release recombinant human TSH (MRrhTSH) augments the effect of (131)I therapy in benign multinodular goiter: results from a multicenter international, randomized, placebo-controlled study'. Together they form a unique fingerprint.

    Cite this